Marie-Eve Chand-Fouché

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design

Karim Fizazi, Stéphanie Foulon, Joan Carles et al. · The Lancet · 2022 · 783 citations · Full text

Medicine, Oncology, Urology +17

Interstitial preoperative high-dose-rate brachytherapy for early stage cervical cancer: Dose–volume histogram parameters, pathologic response and early clinical outcome

Jean‐Michel Hannoun‐Lévi, Marie-Eve Chand-Fouché, Mathieu Gautier et al. · Brachytherapy · 2012 · 28 citations

Medicine, Oncology, Radiation Oncology +16

Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy

Jean‐Michel Hannoun‐Lévi, Marie-Eve Chand-Fouché, C. Dejean et al. · Journal of Contemporary Brachytherapy · 2012 · 23 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Concomitant cervical and transperineal parametrial high-dose-rate brachytherapy boost for locally advanced cervical cancer

Caroline Bailleux, Alexander T. Falk, Marie-Eve Chand-Fouché et al. · Journal of Contemporary Brachytherapy · 2016 · 17 citations · Full text

Medicine, Oncology, Radiation Oncology +16

High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes

Maud le Guyader, D. Lam Cham Kee, Brice Thamphya et al. · Clinical and Translational Radiation Oncology · 2021 · 16 citations · Full text

Medicine, Oncology, Radiation Oncology +17